ChemoCenturyx (CCXI) Sees IPO Price of $14-$16/Share
Get Alerts CCXI Hot Sheet
Join SI Premium – FREE
ChemoCenturyx, Inc. (Nasdaq: CCXI), filed an amended registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering amount is 4 million common shares and ChemoCenturyx sees an IPO price of $14 - $16 per share. ChemoCenturyx plans to list on the Nasdaq Global Market under the ticker "CCXI."
The offering is being made through J.P. Morgan, Citigroup, and Cowen and Company.
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.
The offering is being made through J.P. Morgan, Citigroup, and Cowen and Company.
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karman Line Acquisition closes $200M IPO on Nasdaq
- QNB Corp. prices stock offering at $42 per share on Nasdaq
- Citi cuts Lowe's price target to $260, keeps Buy rating
Create E-mail Alert Related Categories
IPOsRelated Entities
JPMorgan, Citi, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share